The Clorox Company (CLX) financials
NYSE · Consumer Defensive · Household & Personal Products · 9,200 employees · CEO Linda J. Rendle
- Price
- $107.89
- Market cap
- $13.1B
- Enterprise value
- $18.5B Data as of 2026-11-12
- Last report
- Q1 '27 filed 2026-11-02
- Next report
- 2027-02-02 EPS est. $0.98
Revenue (TTM)$7.2B+6.3% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)25.1%+10.2 pp vs a year agoOperating income $1.8B
Net income (TTM)$677M-14.4% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)$453M-28.8% vs a year agoCapex $209M
Diluted EPS (TTM)$5.55-12.9% vs a year agoSum of the last 4 quarters
Net cash-$5.41B-85.8% vs a year agoCash + short-term investments - debt
Valuation & key figures
- Market cap
- $13.1B Updated 1h ago
- Revenue
- $7.2B Trailing 12 months
- Revenue growth
- +14% FY2027 consensus
- Profit margin
- 9.4% Net income / revenue, TTM
- P/E
- 19.4× Forward 18.8× (FY2027)
- P/S
- 1.8× Price / sales, TTM
- EV / EBITDA
- 14.1× TTM
- Free cash flow
- $453M Trailing 12 months
- Net income
- $677M Trailing 12 months
- Revenue estimate
- $7.64B FY2027 consensus
- Earnings
- 2027-02-02 Revenue est. $1.87B · Updated 1h ago
- Dividend
- $1.25 Per payment · 2026-10-28
Key takeaways
Computed from the reported numbers - every statement carries the figure it rests on.
- Last report (2026-11-02): revenue beat by 1.5%, EPS beat by 44.9%Revenue $1.91B vs $1.88B expected (+1.5%); EPS $1.55 vs $1.07 (+44.9%).
- Revenue growth accelerating: 33.3% year on yearQ1 '27 revenue $1.91B, against an average of -5.4% over the four quarters before.
- Operating margin 25.1% (TTM), +10.2 pp on a year agoOperating income grew 78.7% while revenue grew 6.3%.
- 102.4% of pre-tax profit is eaten by non-operating lossesPre-tax income $891M vs operating income $1.8B (TTM). Losses on equity stakes and other one-off items cut net income and EPS - operating income is the cleaner measure of the business.
- Capex 2.9% of revenue (a year ago 3.2%)$209M invested in the last 4 quarters (-3.7% on a year earlier). Free cash flow $453M = 66.9% of net income.
- Returned $729M to shareholders = 160.9% of free cash flowBuybacks $127M (a year earlier $354M), dividends $602M, stock-based pay $47M (TTM). More than the free cash flow: paid from cash or debt.
- Diluted share count down 0.8% in a year122M diluted shares in Q1 '27, 123M a year earlier.
- Net debt $5.41BCash + short-term investments $184M, debt incl. leases $5.59B; a year ago net debt $2.91B.
Last quarter: Q1 '27
Quarter ended 2026-09-30. Compared with the same quarter a year earlier and with the analyst consensus before the report.
Quarter vs a year ago
| Q1 '27 | Year ago | Change | |
|---|---|---|---|
| Revenue | $1.91B | $1.43B | +33.3% |
| Gross margin | 40.4% | 41.7% | -1.3 pp |
| Operating income | $261M | $120M | +117.5% |
| Operating margin | 13.7% | 8.4% | +5.3 pp |
| Net income | $170M | $80M | +112.5% |
| Diluted EPS | $1.39 | $0.65 | +113.8% |
| Operating cash flow | $143M | $93M | +53.8% |
| Capex | $38M | $36M | +5.6% |
| Free cash flow | $105M | $57M | +84.2% |
| R&D | $29M | $28M | +3.6% |
| Stock-based compensation | $9M | $10M | -10.0% |
Reported vs consensus
2026-11-02| Actual | Consensus | vs consensus | |
|---|---|---|---|
| Revenue | $1.91B | $1.88B | +1.5% |
| EPS (as estimated) | $1.55 | $1.07 | +44.9% |
From the report of 2026-11-02 for Q1 '27: revenue and the EPS analysts estimate (often adjusted), so it can differ from the EPS of the statements above.
EPS vs consensus
last 8 reportsRevenue
Where the money comes from - by business line and by region, quarter by quarter.
Revenue, operating income and growth
quarterlyRevenue by business line
stacked, quarterly| Segment | Q1 '27 | y/y | Share of listed | TTM | TTM y/y | 12 quarters |
|---|---|---|---|---|---|---|
| Health and Wellness | $918M | +62.5% | 48.2% | $3.05B | +19.0% | |
| Household | $423M | +16.9% | 22.2% | $1.85B | -3.5% | |
| Lifestyle | $283M | +15.5% | 14.9% | $1.16B | -5.5% | |
| International | $281M | +11.1% | 14.8% | $1.14B | +7.7% |
Margins & cost structure
How much of each unit of revenue is left at each level - and where the costs go.
Margins
quarterlyCosts as % of revenue
quarterlyCash flow & capital allocation
Cash generated, what it is spent on, and what reaches shareholders.
Operating cash flow, capex, free cash flow
quarterlyUses of cash vs operating cash flow
fiscal yearsLast 4 quarters
cash flow statement- Operating cash flow
- $662M
- Capex
- -$209M
- Buybacks
- -$127M
- Dividends
- -$602M
- Acquisitions
- -$2.1B
- Net debt issued
- $2.44B
- Stock-based compensation
- $47M
- Free cash flow
- $453M
- Returned to shareholders / FCF
- 160.9%
Share count and EPS
quarterly, dilutedBalance sheet
Liquidity, investments and debt at each quarter end.
Cash, investments and debt
quarter endsValuation & returns
Today's multiples against the company's own last five fiscal years; analyst targets and ratings.
Multiples and returns
TTM vs 5 fiscal years| Now | 5y average | Where today sits in the 5-year range | |
|---|---|---|---|
| P/E (TTM) | 19.4× | 53.4× | 18.3× – 131.4× |
| EV / EBITDA | 14.1× | 23.0× | 12.7× – 39.4× |
| EV / Sales | 2.6× | 2.7× | 2.5× – 3.0× |
| Price / FCF | 28.9× | 27.3× | 19.5× – 34.5× |
| Price / Book | -337.2× | 69.3× | 31.2× – 129.1× |
| FCF yield | 3.5% | 3.9% | 2.9% – 5.1% |
| Return on invested capital | 22.8% | 16.4% | 11.9% – 24.1% |
| Return on equity | -1,920.6% | 228.1% | 67.7% – 652.2% |
Analysts
Consensus target $88.88 (-17.8%)
range $74.00 – $99.00 · rating Hold
Strong buy0
Buy3
Hold22
Sell4
Strong sell0
Outlook
Analyst consensus for the coming fiscal years and what it implies at today's price.
Consensus estimates
| Fiscal year | Revenue | Growth | EPS | Growth | P/E at today's price | Analysts (EPS) |
|---|---|---|---|---|---|---|
| FY2027 | $7.64B | +13.7% | $5.72 | +19.0% | 18.8× | 11 |
| FY2028 | $7.81B | +2.2% | $6.15 | +7.5% | 17.5× | 10 |
| FY2029 | $8B | +2.4% | $6.59 | +7.1% | 16.4× | 4 |
| FY2030 | $8.28B | +3.5% | $6.80 | +3.2% | 15.9× | 1 |
Financial statements
Every line of the income statement, balance sheet and cash flow statement - 12 quarters and 10 fiscal years, as values, as % of revenue or as growth.
Every reported line
All 113 figures The Clorox Company tagged in its recent 10-Q / 10-K filings, with the official SEC label and definition - including the notes (leases, taxes, buybacks, employees, ...).
| Line (SEC label) | Latest quarter | Year ago | y/y | Latest FY | Prior FY | y/y |
|---|---|---|---|---|---|---|
| Accounts Payable and Accrued Liabilities, Current | $1.69B | $1.93B | -12.4% | $1.83B | $1.49B | +23.0% |
| Accrual for Environmental Loss Contingencies | $28M | $27M | +3.7% | $27M | $28M | -3.6% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $3.12B | $2.96B | +5.6% | $2.91B | $2.82B | +3.2% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$158M | -$165M | +4.2% | -$157M | -$155M | -1.3% |
| Additional Paid in Capital, Common Stock | $1.32B | $1.33B | -0.5% | $1.32B | $1.29B | +2.4% |
| Advertising Expense | $190M | $166M | +14.5% | $770M | $832M | -7.5% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 2.59M | 3.36M | -22.8% | 3.09M | 2.7M | +14.1% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $9M | $10M | -10.0% | $81M | $74M | +9.5% |
| Assets | $7.83B | $5.53B | +41.7% | $5.56B | $5.75B | -3.3% |
| Assets, Current | $1.93B | $1.7B | +13.9% | $1.61B | $1.62B | -0.9% |
| Cash and Cash Equivalents, at Carrying Value | $184M | $166M | +10.8% | $167M | $202M | -17.3% |
| Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months | $25M | $14M | +78.6% | $14M | $8M | +75.0% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $187M | $169M | +10.7% | $170M | $207M | -17.9% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $40M | -$1M | +4,100.0% | -$37M | -$161M | +77.0% |
| Commercial Paper | $1.18B | $218M | +439.0% | $4M | $4M | 0.0% |
| Common Stock, Dividends, Per Share, Declared | $2.50 | $2.48 | +0.8% | $4.88 | $4.80 | +1.7% |
| Common Stock, Par or Stated Value Per Share | $1.00 | $1.00 | 0.0% | $1.00 | $1.00 | 0.0% |
| Common Stock, Shares Authorized | 750M | 750M | 0.0% | 750M | 750M | 0.0% |
| Common Stock, Shares, Issued | 131M | 131M | 0.0% | 131M | 131M | 0.0% |
| Common Stock, Shares, Outstanding | 121M | 122M | -0.7% | 123M | 124M | -1.2% |
| Common Stock, Value, Issued | $131M | $131M | 0.0% | $131M | $131M | 0.0% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest | $3M | $2M | +50.0% | $14M | $12M | +16.7% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $169M | $72M | +134.7% | $808M | $618M | +30.7% |
| Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest | $172M | $74M | +132.4% | $822M | $630M | +30.5% |
| Cost of Goods and Services Sold | $1.14B | $833M | +36.3% | $3.89B | $4.05B | -3.8% |
| Deferred Income Tax Expense (Benefit) | $21M | $84M | -75.0% | -$18M | -$100M | +82.0% |
| Deferred Income Tax Liabilities, Net | $16M | $20M | -20.0% | $20M | $22M | -9.1% |
| Defined Benefit Plan, Net Periodic Benefit Cost (Credit) | $0 | $1M | -100.0% | $2M | $14M | -85.7% |
| Depreciation, Depletion and Amortization | $74M | $56M | +32.1% | $219M | $235M | -6.8% |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal | $02026-03-31 | $0 | – | -$118M | -$240M | +50.8% |
| Dividends, Common Stock | $307M | $306M | +0.3% | – | – | – |
| Earnings Per Share, Basic | $1.39 | $0.65 | +113.8% | $6.56 | $2.26 | +190.3% |
| Earnings Per Share, Diluted | $1.39 | $0.65 | +113.8% | $6.52 | $2.25 | +189.8% |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $0 | -$1M | +100.0% | $0 | -$26M | +100.0% |
| Effective Income Tax Rate Reconciliation, Percent | 16.4% | 23.4% | -29.9% | 23.6% | 26.5% | -10.9% |
| Foreign Currency Transaction Gain (Loss), before Tax | -$1M | -$1M | 0.0% | -$2M | -$25M | +92.0% |
| Gain (Loss) on Investments | $0 | $9M | -100.0% | $18M | $20M | -10.0% |
| Goodwill | $1.94B | $1.23B | +58.4% | $1.23B | $1.23B | +0.1% |
| Gross Profit | $770M | $596M | +29.2% | $3.21B | $3.05B | +5.4% |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | $207M | $107M | +93.5% | $1.08B | $398M | +170.9% |
| Income (Loss) from Equity Method Investments | $1M | $1M | 0.0% | $4M | $5M | -20.0% |
| Income Tax Expense (Benefit) | $34M | $25M | +36.0% | $254M | $106M | +139.6% |
| Increase (Decrease) in Accounts Payable and Accrued Liabilities | -$68M | -$40M | -70.0% | -$124M | -$140M | +11.4% |
| Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable | -$63M | -$107M | +41.1% | $2M | -$147M | +101.4% |
| Increase (Decrease) in Inventories | $4M | $55M | -92.7% | -$63M | -$55M | -14.5% |
| Increase (Decrease) in Prepaid Expense and Other Assets | $44M | $41M | +7.3% | $9M | -$25M | +136.0% |
| Increase (Decrease) in Receivables | -$42M | -$118M | +64.4% | $145M | $34M | +326.5% |
| Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements | 408K | 389K | +4.9% | 762K | 630K | +21.0% |
| Interest Expense | $52M | $23M | +126.1% | $88M | $90M | -2.2% |
| Inventory, Finished Goods, Net of Reserves | $629M | $500M | +25.8% | $447M | $556M | -19.6% |
| Inventory, LIFO Reserve | $84M | $90M | -6.7% | $80M | $98M | -18.4% |
| Inventory, Net | $774M | $577M | +34.1% | $523M | $637M | -17.9% |
| Inventory, Noncurrent | $6M | – | – | $0 | $2M | -100.0% |
| Inventory, Raw Materials and Supplies, Net of Reserves | $181M | $149M | +21.5% | $141M | $172M | -18.0% |
| Inventory, Work in Process, Net of Reserves | $54M | $18M | +200.0% | $15M | $9M | +66.7% |
| Investment Income, Interest and Dividend | $1M | $2M | -50.0% | $9M | $23M | -60.9% |
| Letters of Credit Outstanding, Amount | $0 | $0 | – | $0 | $0 | – |
| Liabilities | $7.71B | $5.39B | +43.1% | $5.08B | $5.26B | -3.4% |
| Liabilities and Equity | $7.83B | $5.53B | +41.7% | $5.56B | $5.75B | -3.3% |
| Liabilities, Current | $2.95B | $2.23B | +32.2% | $1.92B | $1.57B | +21.9% |
Source: SEC companyfacts (XBRL of every 10-Q / 10-K). Cash-flow quarters are derived from the year-to-date figures the 10-Q tags. Segment breakdowns are tagged with dimensions and are shown in the segment section instead.
Sources
Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-09-30, 10-K 2026-06-30, 10-Q 2026-03-31, 10-Q 2025-12-31, 10-Q 2025-09-30, 10-K 2025-06-30, 10-Q 2025-03-31, 10-Q 2024-12-31, 10-Q 2024-09-30
Data as of 2026-11-12